Investigational drug · Phase 2
RYZ801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RYZ801"
First trial start
2025
Sep 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RYZ801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RYZ801" as an intervention, largest first.
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCPivotal-lookingRecruiting
RayzeBio, Inc.Industry
NCT06726161 · 590 participants (planned) · Start Sep 5, 2025 · Primary completion Jun 2030
Drug: RYZ801 · For: Hepatocellular Carcinoma (HCC)
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Glypican-3 as a Theranostic Target in Hepatocellular Carcinoma.
Weber WA, Eiber M, Lapa C, et al. · J Nucl Med 2026
Also in development for Hepatocellular Carcinoma (HCC)
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- CobolimabPhase 32 trials
GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.